复发/难治性急性淋巴细胞白血病贝林妥欧单抗治疗期间耐药与复发的相关因素
该回顾性分析纳入65例接受贝林妥欧单抗治疗的复发/难治性急性淋巴细胞白血病患者,完全缓解率为51%,其中15例(45%)缓解者后续接受异基因造血干细胞移植。高白血病负荷、既往或当前髓外病变预示较低缓解率,治疗失败时髓外病变和CD19阴性/暗淡表达常见。
要点
- 完全缓解率51%,15例(45%)缓解者接受异基因造血干细胞移植。
- 骨髓原始细胞>50%(P=0.02)、既往髓外病变史(P=0.005)、用药时活动性髓外病变(P=0.05)预示较低完全缓解率。
- 治疗失败时髓外病变和CD19阴性/暗淡表达常见, pretreatment中等/强CD19表达(P=0.01)和既往髓外病变史(P=0.04)是进展/复发时出现髓外病变的危险因素。
核心结论
- 髓外病变和CD19阴性表达是复发/难治性急性淋巴细胞白血病贝林妥欧单抗治疗失败时的常见表现。
- 除高白血病负荷外,当前或既往髓外病变与贝林妥欧单抗较低缓解率相关;较高CD19表达及既往髓外病变史与治疗失败时出现髓外病变相关。
研究设计与样本
- 回顾性分析65例接受贝林妥欧单抗治疗的复发/难治性急性淋巴细胞白血病患者,评估白血病缓解预测因素及复发/耐药的临床模式,重点关注CD19表达下调和髓外病变。
主要发现
- 完全缓解率为51%,15例(45%)缓解者在完全缓解后接受异基因造血干细胞移植。
- 骨髓原始细胞>50%(P=0.02)、既往髓外病变史(P=0.005)、开始贝林妥欧单抗时活动性髓外病变(P=0.05)预示较低完全缓解率。
- 难治病例中,13例(41%)有髓外病变进展证据,CD19表达阴性或暗淡者分别占18%和23%。
- 缓解者中,20例(61%)后续复发,其中8例(40%)发生髓外病变复发,可评估病例中CD19表达阴性或暗淡者分别占35%和6%。
- 治疗前中等/强CD19表达(P=0.01)和急性淋巴细胞白血病病程中既往髓外病变史(P=0.04)是进展/复发时出现髓外病变的危险因素;无治疗前因素预测CD19阴性急性淋巴细胞白血病进展/复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We retrospectively analyzed 65 patients with refractory/relapsed (r/r) ALL who were treated with blinatumomab for predictors of leukemia response as well as clinical patterns of relapse and resistance with particular focus on downregulation of CD19 expression and extramedullary disease (EM-ALL). The complete remission (CR) rate was 51%, and 15 (45%) responders underwent allogeneic hematopoietic cell transplantation (HCT) in CR. High leukemia burden (bone marrow blasts >50%) (P = .02), history of prior EM-ALL (P = .005), and active EM-ALL at the time of initiating blinatumomab (P = .05) predicted lower CR rate. Among refractory cases, 13 (41%) had evidence of EM-ALL progression, and CD19 expression was negative or dim in 18% and 23%, respectively. Among responders, 20 (61%) subsequently relapsed among whom EM-ALL relapse occurred in 8 (40%) patients, and CD19 expression was negative or dim in 35 and 6% of evaluable cases, respectively. Pretreatment moderate/strong CD19 expression (P = .01) and history of prior EM-ALL during ALL course (P = .04) were risk factors for developing EM-ALL at progression/relapse. However, no pretreatment factors predicted progression/relapse with CD19-negative ALL. Overall-survival (OS) and even-free survival were improved for patients underwent allogeneic HCT compared to responders who did not. Furthermore, OS was superior for patients responded to blinatumomab compared to those who did not. Extramedullary and CD19-negative disease are common during blinatumomab failure in r/r ALL. In addition to high leukemia burden, concurrent or prior history EM-ALL were associated with lower response to blinatumomab. Higher CD19 expression as well as prior history of EM-ALL were associated with EM-ALL at the time of blinatumomab failure.
引用
- Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017. PMID: 28494518. doi:10.1002/ajh.24783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。